- Final Overall Survival: Fulvestrant 500 mg vs 250 mg in the Randomized CONFIRM Trial2014 | 1. lékařská fakulta
- Comparing duration of response and duration of clinical benefit between fulvestrant treatment groups in the CONFIRM trial: application of new methodology2013 | 1. lékařská fakulta
- Výsledky klinické studie fáze III CONFIRM porovnávající fulvestrant v dávce 250 mg s dávkou 500 mg u postmenopauzálních žen s estrogen pozitivním pokročilým karcinomem prsu2010 | 1. lékařská fakulta
- Clinical significance of gastrointestinal and flushing events in patients with multiple sclerosis treated with delayed-release dimethyl fumarate2015 | 1. lékařská fakulta
- Effect of delayed-release dimethyl fumarate on no evidence of disease activity in relapsing-remitting multiple sclerosis: integrated analysis of the phase III DEFINE and CONFIRM studies2017 | 1. lékařská fakulta